Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on March 24, 2010. The report discloses corporate governance changes regarding the departure of a senior officer and the appointment of new officers effective March 26, 2010.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: William D. "Chip" Clark resigned as Senior Vice President, Chief Business Officer, and Secretary to pursue other opportunities. His resignation is effective March 26, 2010.
- Appointment: Stephanie R. Irish, Acting Chief Financial Officer and Treasurer, was appointed as Secretary effective upon Mr. Clark's resignation. There is no change to her compensatory arrangements.
- Title Change: Dr. John J. Feeney III's title was changed from Acting Chief Medical Officer to Chief Medical Officer. There is no change to his compensatory arrangements.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the disclosure of the officer changes described above.
Key Facts for Investor Verification
- Confirm the effective date of William D. Clark's departure (March 26, 2010).
- Verify the new leadership structure with Stephanie R. Irish as Secretary and Dr. John J. Feeney III as Chief Medical Officer.
- Note that no changes to compensation were made for the appointed or promoted officers.